INGELHEIM, Germany - Monday, May 23rd 2016 [ME NewsWire]
Aims to identify maladaptive brain circuits to find new approaches for treating psychiatric diseases
Second Boehringer Ingelheim crowdsourcing project with BioMed X builds on success of previous project focused on epigenetic drivers of COPD
New research team at the BioMed X Innovation Center will complement Boehringer Ingelheim’s broad research and development efforts in psychiatric diseases
(BUSINESS WIRE)-- Boehringer Ingelheim and BioMed X announced today that they have established a new research team of outstanding scientists from around the world that will conduct research to identify novel approaches for the treatment of patients with psychiatric diseases. The members of this team had submitted the most promising solution approaches in a crowdsourcing competition.
According to the World Health Organization, mental illness - together with substance abuse disorders - remains the leading cause of disability worldwide. At least 450 million people suffer from mental health problems. The global economic burden of mental illness is larger than for cancer, cardiovascular disease or diabetes and continues to grow – with significant health, social and economic consequences. As currently available treatment options leave many patients unsatisfactorily treated, more effective medicines for mental diseases are urgently needed.
“We are excited about applying the innovative approach of crowdsourcing to harness the creativity of the scientific community and combine it with our internal research and development capabilities, to discover the next generation of medicines for patients with psychiatric diseases who currently have insufficient treatment options,” said Corporate Senior Vice President Clive R. Wood, Head of Discovery Research of Boehringer Ingelheim. “Our scientists will work closely with the new team we are establishing with our partner BioMed X, thereby further supporting our ambition to be an innovation leader in psychiatric diseases.”
Christian Tidona, founder and Managing Director of BioMed X explained: “With this new neuroscience research group our center is growing to over 60 top researchers from around the world. We are excited about our strong partnership with Boehringer Ingelheim which is driven by scientific excellence and mutual trust.”
The interdisciplinary team will focus on the generation of novel therapeutic approaches for psychiatric diseases by developing a highly integrated brain microcircuit model which includes authentic neuronal and non-neuronal cells and supports functional readouts with sufficient robustness and throughput for drug discovery. Michał Ślęzak will head the research team that will be established in the BioMed X Innovation Center located on the campus of the University of Heidelberg, Germany. The new project follows on the successful establishment of a group to identify novel epigenetic drivers to find new approaches for treating COPD and underscores Boehringer Ingelheim’s long term sustainable collaboration approach.
The new crowdsourcing initiative is just one example of the increasing focus Boehringer Ingelheim puts on partnering, constantly seeking new innovative collaboration models to adapt to the needs of its partners and maximize mutual benefit. The research team will be sponsored by Boehringer Ingelheim for two years with the option to extend the funding period up to a total of four years. Further details of the agreement are not disclosed.
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
For references and notes to editor, please visit:
Dr. Reinhard Malin
Director Corporate Communications – Oncology and Pipeline
Tel. +49 (6132) 77-90815